Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.16 +0.51 (+2.07%)
Official Closing Price Updated: 6:30 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Most active S&P500 stocks in Wednesday's session
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
This big pharma company's juicy dividend is looking even more attractive. 
Via The Motley Fool
Topics Earnings
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions
Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year.... 
Via StockStory
Topics Earnings
PFE Q2 Deep Dive: Margin Expansion and R&D Pipeline Fuel Outlook Amid Policy Uncertainty
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full... 
Via StockStory
Topics World Trade
The Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call
Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance... 
Via StockStory
Topics Earnings
Trading Radar For August 13: Paytm, HUL, Cochin Shipyard, Karnataka Bank, And Jindal Steel Are On Stocks Watchlist
BPCL, Pfizer, Vishal Mega Mart, among others, are expected to post their quarterly earnings today. 
Via Stocktwits
Topics Economy Energy
Pfizer Raises Its Guidance And Analysts Up Their Targets - PFE Stock Looks Cheap
Pfizer, Inc. stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year. 
Via Talk Markets
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued
According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season. 
Via Stocktwits
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy. 
Via Benzinga
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners. 
Via The Motley Fool
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
From Pfizer Inc.
Via Business Wire
Trading Radar For August 12: Hindalco, Adani Enterprises, Bata, Pfizer, Ashoka Buildcon, And Inox Green Are On Stocks Watchlist
Via Stocktwits
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today
Investing is about looking ahead. 
Via The Motley Fool
Topics Intellectual Property
Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock?
It was a rare breath of fresh air for shareholders. 
Via The Motley Fool
Topics Intellectual Property
Stay informed about the most active stocks in the S&P500 index on Monday's session.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one. 
Via The Motley Fool
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern on board to fill in gaps. 
Via Benzinga
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage. 
Via Benzinga
3 Large-Cap Stocks with Promising Prospects
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
2 Stocks to Buy With $5,000 and Hold for a Decade
These two stocks come from completely different industries, but each could boost a long-term investor's returns. 
Via The Motley Fool
2 Beaten-Down Stocks to Buy and Hold
The market has been tough on these stocks, but a closer look at each is warranted. 
Via The Motley Fool
Topics Intellectual Property
Meet the 7.3% Yield Dividend Stock That Could Soar in 2026
This stock recently bounced on strong Q2 earnings, and the fun could be just getting started. 
Via The Motley Fool
Topics Government World Trade
Positive Gems Becomes the World’s Most Followed Modern Pharmaceutical Brand
Via Get News
Topics Intellectual Property
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
1 Safe-and-Steady Stock to Target This Week and 2 We Avoid
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s... 
Via StockStory
Upcoming Earnings Calls This Week: August 4th - August 10th, 2025
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial... 
Via MarketMinute
Topics Artificial Intelligence Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.